HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

por Volk, JE, Hessol, NA, Gray, GE, Kublin, JG, Churchyard, G, Mlisana, K, Nchabeleng, M, Buchbinder, SP, Bekker, L
Publicado 2012

P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine

por Latka, M, Grey, G, Fielding, K, Bekker, L, Mlisana, K, Nchabeleng, M, DeBruin, G, Allen, M, Kublin, J, Churchyard, G
Publicado 2009

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa

por Allen, MA, Gray, G, Churchyard, G, Bekker, L, Nchabeleng, M, Mlisana, K, Metch, B, Moodie, Z, Roux, S, Mathebula, M, Bennie, T, Kublin, J
Publicado 2009

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial

por de Bruyn, G, Mlisana, K, Metch, B, Churchyard, G, Nchabeleng, M, Bekker, L, Roux, S, Naicker, N, Latka, M, Corey, L, Kublin, J, Gray, G
Publicado 2009

Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen

por Green, E., Obi, C.L., Nchabeleng, M., de Villiers, B.E., Sein, P.P., Letsoalo, T., Hoosen, A.A., Bessong, P.O., Ndip, R.N.
Publicado 2010

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

por Gray, GE, Bekker, L, Churchyard, G, Nchabeleng, M, Mlisana, K, de Bruyn, G, Roux, S, Mathebula, M, Latka, M, Bennie, T, Metch, B, Moodie, Z, Allen, M, Eaton, N, Kublin, J
Publicado 2009